AstraZeneca and Ionis missed a key heart-drug trial goal, shifting attention to BridgeBio’s approved ATTR-CM treatment.

A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.

The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a ...

AstraZeneca and Ionis announced on Thursday that their late-stage CARDIO-TTRansform trial for eplontersen (Wainua) failed to ...

The British drugmaker lost roughly $27 billion in market value after Wainua failed to reduce cardiovascular deaths and recurring heart events ...

AstraZeneca shares fell sharply Thursday after the pharmaceutical giant reported that its experimental use of Wainua failed ...

AstraZeneca (AZN 7.39%) fell over 8% ahead of the opening bell after a late-stage clinical trial for its heart disease drug ...

Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new study. Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to ...

There’s an active recall on at least 944,142 bottles of heart and kidney medications sold nationwide, according to the U.S.

A study reveals that non-cardiovascular medications increase hospital readmission risks in heart failure patients, ...